Warning! GuruFocus has detected 6 Severe warning signs with OSMT. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
NAS:OSMT (USA) Also Trade In: Germany
Current and historical daily P/E ratio for OSMT (Osmotica Pharmaceuticals PLC) from 2018 to May 05 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Osmotica Pharmaceuticals PLC stock (OSMT) PE ratio as of May 05 2021 is 0. More Details
Osmotica Pharmaceuticals PLC PE Ratio (TTM) Historical Data
View and export this data going back to 2018. Start your Free Trial
Osmotica Pharmaceuticals PLC PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
400 Crossing Boulevard, Bridgewater, NJ, USA, 08807
Osmotica Pharmaceuticals PLC is a fully-integrated biopharmaceutical company. It is focused on developing, manufacturing and commercializing specialty products. The product portfolio of the group includes specialty neurology and women's health products, which are primarily complex formulations of generic drugs. Osmotica has a lateâ€‘stage development pipeline by two NDA candidates that recently completed Phase III clinical trials: arbaclofen ER for spasticity in multiple sclerosis patients and RVLâ€‘1201 for the treatment of acquired blepharoptosis, or droopy eyelid.